Xenetic Biosciences, Inc. XBIO 深 滬
等待開盤 11-26 09:30:00 美东时间
2.52
+0.060
+2.44%
華盛通- 最 高2.535
- 今 開2.41
- 成交量 1.92万股
- 最 低 2.41
- 昨 收 2.46
- 總市值 388.61万
- 52周最高 13.93
- 市盈率 靜 --
- 換手率 1.25%
- 52周最低 2.20
- 委 比 76.21%
- 總股本 154.21万
- 歷史最高 1074.00
- 量 比 0.22
- 振 幅 5.08%
- 歷史最低 2.20
- 每 手 1
- 風險率 0.87%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Xenetic Biosciences Executes 4-Month Extension Of Collaboration With Institute Investigator At Scripps Research To Advance Development Of R&D Program Evaluating Combination Of Systemic Dnase I And CAR T-Cell Therapies
Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced it has
11-19 21:47
Xenetic Biosciences Q3 EPS $(0.33) Beats $(0.49) Estimate, Sales $1.027M Beat $630.000K Estimate
Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.49) by 32.65 percent. This is a 17.86 percent decrease over losses of $(0.28) per share
11-13 21:49
Xenetic Biosciences Announces Public Offering Pricing
Xenetic Biosciences ( ($XBIO) ) has provided an announcement. On October 10, 20...
10-14 21:21
Xenetic Biosciences Prices Offering Of 735K Common Shares At $6.12/Shr For Gross Proceeds Of ~$4.5M
Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced the
10-10 21:33
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Xenetic Biosciences (NASDAQ:XBIO) stock moved upwards by 137.1% to $10...
10-09 01:06
Nasdaq Gains 150 Points; US Mortgage Applications Decline
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining more ...
10-08 22:22
Why Confluent Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
Shares of Confluent Inc (NASDAQ:CFLT) rose sharply in pre-market trading. Confl...
10-08 16:43
Xenetic Biosciences reports Q2 results
Xenetic Biosciences press release (NASDAQ:XBIO): Q2 Net loss for the quarter ended June 30, 2025 was approximately $0.7 million. Research & development expenses for the three months ended June 30, 202...
08-13 22:16
Xenetic Biosciences Q2 EPS $(0.45) Beats $(0.65) Estimate, Sales $589.897K Miss $720.000K Estimate
Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.65) by 30.77 percent. This is a 45.78 percent increase over losses of $(0.83) per share
08-13 20:09
Xenetic Biosciences Reports Improved Financial Performance
Xenetic Biosciences, Inc. ( ($XBIO) ) has released its Q2 earnings. Here is a b...
08-13 12:32
